文献速递免疫规划

女孩和男孩接种一剂HPV疫苗后的免疫应答及3年或更长时间后接种第二剂的影响

Immune response after one dose of HPV vaccine among girls and boys and the impact of a second dose given after 3 or more years.
PubMed 文献 · Vaccine · 2025-07-14

该单组描述性研究纳入加拿大魁北克市地区参加学校接种计划的青少年,女孩接种一剂4vHPV、男孩接种一剂9vHPV,3-10年后采血,随后分别接种一剂9vHPV或2vHPV加强剂,1个月后再次采血。结果显示单剂后多年仍可检出HPV16/18抗体,第二剂后抗体几何平均浓度显著升高。

要点

  • 男孩接种一剂9vHPV后4年,HPV16和HPV18抗体可检出率分别为96.5%和97.9%。
  • 女孩接种一剂4vHPV后3-10年,HPV16和HPV18抗体可检出率分别为95.0%和93.3%。
  • 第二剂后1个月所有参与者HPV16/18均血清阳性,抗体几何平均浓度显著升高。

核心结论

  • 单剂HPV疫苗在女孩(4vHPV)和男孩(9vHPV)中诱导强烈且持久的免疫应答,数年后接种第二剂出现显著的抗体回忆性加强。
  • 这些发现提示两性中单剂或延迟加强策略的潜力,并支持显示单剂方案有效性的研究。

研究设计与样本

  • 单组描述性研究,对象为加拿大魁北克市地区参加公立学校接种计划的青少年,女孩接种一剂4vHPV、男孩接种一剂9vHPV。
  • 初次接种后3-10年采集血样,随后女孩接种一剂9vHPV、男孩接种一剂2vHPV加强剂,1个月后再次采血,采用M9ELISA进行血清学检测。
  • 研究注册于ClinicalTrials.gov(NCT03431246)。

主要发现

  • 141名12至14岁男孩在初始9vHPV剂量后4年,HPV16和HPV18抗体可检出率分别为96.5%和97.9%。
  • 13至24岁女孩在接种一剂4vHPV后3-10年,HPV16和HPV18抗体可检出率分别为95.0%和93.3%。
  • 第二剂后1个月,所有参与者HPV16/18均血清阳性,抗体几何平均浓度显著升高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Initially approved as a three-dose regimen, evolving evidence has supported the efficacy of reduced-dose schedules. Single-dose HPV vaccine data among males remain scarce. This study assesses the persistence of antibodies against HPV16/18 following a single HPV vaccine dose and the immune response to a subsequent delayed dose administered at least three years later in girls and boys. METHODS: This single-group descriptive study involved youth from the Quebec City area, Canada, who received a single dose of 4vHPV (girls) or 9vHPV (boys) as part of the public school-based vaccination program. A blood sample was collected 3-10 years post-initial vaccination. Girls and boys then received one 9vHPV or 2vHPV booster dose, respectively, and had a second blood draw one month later. Serological assays were conducted using M9ELISA. RESULTS: Four years after the initial 9vHPV dose, among 141 boys aged 12 to 14 years 96.5 % and 97.9 % had detectable antibodies against HPV16 and HPV18, respectively. Among girls aged 13 to 24 years vaccinated 3-10 years prior with one 4vHPV dose, 95.0 % (HPV16) and 93.3 % (HPV18) had detectable antibodies. One-month post-second dose administration, all participants were seropositive for HPV16/18, with significant increases in geometric mean concentrations (GMCs). CONCLUSION: A single dose induces a strong and lasting immune response in girls (4vHPV) and boys (9vHPV), with a significant antibody anamnestic boost following a second dose administered several years later. These findings indicate the potential for a single-dose or a delayed booster strategy in both sexes, and support studies showing effectiveness of single-dose schedules. TRIAL REGISTRATION: The study is registered with ClinicalTrials.gov (NCT03431246).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Guzun N, Ouakki M, Panicker G, et al. Immune response after one dose of HPV vaccine among girls and boys and the impact of a second dose given after 3 or more years. Vaccine. 2025. PMID: 40664165. doi:10.1016/j.vaccine.2025.127475

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。